In this section:

Efficacy in Sickle Cell Disease

EXJADE Removes Toxic Iron in Patients With Sickle Cell Disease

EXJADE removes hepatic iron

23% Reduction in Liver Iron Concentration With 30 mg/kg/day Dose1
Reductions in Mean Serum Ferritin

Effective short-term serum ferritin reductions that carry through 1 year

Reductions in Mean Serum Ferritin With
30 mg/kg/day Dose of EXJADE1
EXJADE Reduces Hepatic Iron Concentration

Data from Study 109, a 1-year, open-label, phase II trial evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean+SD) in LIC determined according to assigned treatment category for EXJADE.2


Follow-up for the pivotal SCD trial was extended. Learn more about the long-term data.